Barbara Balser, VMD

Founder, Executive Vice President, and Chief Scientific Officer

Barbara Balser, VMD, co-founder, Executive Vice President and Chief Scientific Officer of Veristat, is primarily responsible for strategic planning and consulting, medical oversight and production of regulatory submission documents. Barbara has more than 30 years of clinical research experience that encompasses both the pharmaceutical and contract research organization industries. Her experience includes oversight and production of Investigational New Drug (IND) applications, regulatory agency briefing documents, preparation for and representation at advisory panel meetings, and consultation across Phase 1 to 4 trials in multiple therapeutic areas with a specific focus in oncology and anti-infectives.

Barbara has participated in the writing, oversight, and submission of multiple marketing applications to US, Canadian, Japanese, and European Union regulatory authorities. Prior to co-founding Veristat, Barbara served as Associate Director of Clinical Research at Medical & Technical Research Associates, Inc. where she was responsible for strategic planning, design, and management of clinical development programs; preparation and submission of regulatory applications; and scientific communications.Barbara began her career in the pharmaceutical industry at Miles, Inc. (currently Bayer Corporation). In her capacity as Assistant Director of Clinical Research at Miles, Barbara assisted with strategic planning for the clinical development of anti-infective compounds from Phases 2 to 4 and with the planning, writing, and compilation of two successful NDAs for anti-infective products. Prior to joining the pharmaceutical and biotech industry, Barbara practiced veterinary medicine at a private veterinary hospital. Barbara holds a BS in Chemical Engineering from the University of Pennsylvania, School of Engineering and Applied Science, and a VMD from the University of Pennsylvania, School of Veterinary Medicine. When Barbara isn’t busy traveling the world for our clients, she enjoys spending time on the beach with a good book.

Kim Boericke

Chief Executive Officer

Kim Boericke is the Chief Executive Officer of Veristat and is a member of the company’s Executive Leadership Team. She is responsible for developing and implementing the global strategy for the organization which is focused on providing data analytics and insights to accelerate research and development and approvable regulatory submissions. She is known for rigorous standards and an execution-focused approach that supports regulatory clarity and operational consistency across complex development programs. She brings a leadership approach that is grounded in accountability and collaboration with a sharp focus on client and patient outcomes.

A scientifically astute executive with more than 25 years in the clinical research industry, Kim is recognized for expertise in clinical trial design and the implementation of decentralized clinical trials across global regions and therapeutic areas, with an execution-focused style that supports regulatory clarity and operational consistency. She joined Veristat in 2024 as Chief Operating Officer (COO) and previously served as COO at THREAD, with additional executive and senior leadership roles at ICON, IQVIA, ClinTrials, INC Research, Duke Clinical Research Institute and i3 Research. She also served on the board of Mapi Trust as the Chairwoman and an independent director.

Kim graduated from Duke University with a degree in biology and is the author of more than 15 published articles. She is an active mentor within the clinical operations community and a strong advocate for patient centricity, inclusion, and STEM education.